News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
CGHS would give robust coverage to pensioners and with new innovations and practices
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
